|
WO2020191207A1
|
|
Therapeutic methods for treating hepatitis b
|
|
TW202035359A
|
|
Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same
|
|
WO2020097520A1
|
|
Cationic lipids containing silicon
|
|
WO2020097548A1
|
|
Lipid nanoparticle formulations
|
|
WO2020097540A1
|
|
Lipid nanoparticle formulations
|
|
WO2020097493A1
|
|
Negatively charged peg-lipid conjugates
|
|
WO2020093053A1
|
|
Bivalent targeted conjugates
|
|
JOP20190214A1
|
|
subbstituted Dihydroindene-4-Carboxamides and Analogs Thereof, and Methods Using Same
|
|
WO2020046941A1
|
|
Crystalline forms of substituted dihydroindene-4-carboxamide compounds and methods of preparing and using same
|
|
TW202019406A
|
|
Substituted tetrahydrocyclopenta[c]pyrroles, substituted dihydropyrrolizines, analogues thereof, and methods of using same
|
|
WO2019246427A1
|
|
Crystalline forms of pyridinone-containing tricyclic compounds and methods of preparing and using same
|
|
WO2019200114A1
|
|
Methods for preparing substituted dihydroindene-4-carboxamide compounds
|
|
KR20200142529A
|
|
Method for producing substituted pyridinone-containing tricyclic compound
|
|
US2021052585A1
|
|
Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
|
|
US2019169185A1
|
|
Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same
|
|
US2019169128A1
|
|
Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same
|
|
WO2019051257A2
|
|
Methods for treating hepatitis b infections
|
|
TW201912153A
|
|
Compounds, compositions and methods for treating hepatitis b
|
|
TW201919653A
|
|
Therapeutic compositions and methods for treating hepatitis B
|
|
TW201907009A
|
|
Therapeutic composition and method for treating hepatitis B
|
